Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Hemolytic Uremic Syndrome in a Lung Cancer Patient Treated with Gemcitabine

Gemcitabine을 사용한 폐암환자에서 발생한 용혈성 요독증후군 1예

  • Park, Youn-Jung (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Yang, Keun-Suk (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Jung, Hong-Soon (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Nam, Hee-Chul (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Jung, Seung-Hye (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Kim, Boo-Gyoung (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Kim, Ka-Young (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Kim, Jung-Ho (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Kim, Young-Ok (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Yun, Yu-Seon (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • 박윤정 (가톨릭대학교 의과대학 내과학교실) ;
  • 양근석 (가톨릭대학교 의과대학 내과학교실) ;
  • 정홍순 (가톨릭대학교 의과대학 내과학교실) ;
  • 남희철 (가톨릭대학교 의과대학 내과학교실) ;
  • 정승혜 (가톨릭대학교 의과대학 내과학교실) ;
  • 김부경 (가톨릭대학교 의과대학 내과학교실) ;
  • 김가영 (가톨릭대학교 의과대학 내과학교실) ;
  • 김정호 (가톨릭대학교 의과대학 내과학교실) ;
  • 김영옥 (가톨릭대학교 의과대학 내과학교실) ;
  • 윤유선 (가톨릭대학교 의과대학 내과학교실)
  • Received : 2011.11.11
  • Accepted : 2011.12.31
  • Published : 2012.02.29
Download PDF
⟨ Previous Next ⟩

Abstract

Hemolytic uremic syndrome (HUS) is a rare disorder characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS arises from a wide spectrum of conditions, and chemotherapeutic agents have been reported to be associated with HUS, including Mitomycin, Cisplatin, Bleomycin, and Gemcitabine. A 76-year-old man treated with Gemcitabine due to non-small cell lung cancer developed clinical and laboratory findings compatible with HUS. Gemcitabine was ceased and hemodialysis and plasma exchange were utilized and he recovered. A high level of suspicion for HUS is necessary when cancer patients are treated with Gemcitabine, and prompt recognition and treatment are also essential.

Keywords

References

  1. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600. https://doi.org/10.1056/NEJMra020528
  2. Blackall DP, Marques MB. Hemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generation. Am J Clin Pathol 2004;121 Suppl:S81-8.
  3. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. https://doi.org/10.1186/1750-1172-6-60
  4. Gore EM, Jones BS, Marques MB. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? J Clin Apher 2009; 4:209-14.
  5. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999;85:2023-32. https://doi.org/10.1002/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2
  6. Saif MW, Xyla V, Makrilia N, Bliziotis I, Syrigos K. Thrombotic microangiopathy associated with gemcitabine: rare but real. Expert Opin Drug Saf 2009;8:257-60. https://doi.org/10.1517/14740330902942299
  7. Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol 2007;8:634-41. https://doi.org/10.1016/S1470-2045(07)70203-6
  8. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001;60:831-46. https://doi.org/10.1046/j.1523-1755.2001.060003831.x
  9. Flombaum CD, Mouradian JA, Casper ES, Erlandson RA, Benedetti F. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis;33:555-62.
  10. Saif MW, McGee PJ. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. JOP 2005;6:369-74.
  11. Duperray A, Tranqui L, Alix JL, Cordonnier D. Effect of mitomycin C on prostacyclin synthesis by human endothelial cells. Biochem Pharmacol 1988;37:4753-7. https://doi.org/10.1016/0006-2952(88)90348-6
  12. Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin- based chemotherapy. Oncology 1985;42:296-300. https://doi.org/10.1159/000226049
  13. Porta C, Danova M, Riccardi A, Bobbio-Pallavicini E, Ascari E. Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc 1999; 74:570-4. https://doi.org/10.4065/74.6.570
  14. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006;108: 1267-79. https://doi.org/10.1182/blood-2005-10-007252
  15. Walker RW, Rosenblum MK, Kempin SJ, Christian MC. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer 1989;64:1017-20. https://doi.org/10.1002/1097-0142(19890901)64:5<1017::AID-CNCR2820640508>3.0.CO;2-N
  16. Werner TL, Agarwal N, Carney HM, Rodgers GM. Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol 2007;82:295-8. https://doi.org/10.1002/ajh.20783
  17. Oberic L, Buffet M, Schwarzinger M, Veyradier A, Clabault K, Malot S, et al. Cancer awareness in atypical thrombotic microangiopathies. Oncologist 2009;14:769-79. https://doi.org/10.1634/theoncologist.2009-0067
  18. Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003;14:1072-81. https://doi.org/10.1097/01.ASN.0000060805.04118.4C
  19. Fakhouri F, Frémeaux-Bacchi V. Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura? Nat Clin Pract Nephrol 2007;3:679-87. https://doi.org/10.1038/ncpneph0670
  20. Bharthuar A, Egloff L, Becker J, George M, Lohr JW, Deeb G, et al. Rituximab-based therapy for gemcitabine- induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Cancer Chemother Pharmacol 2009;64:177-81. https://doi.org/10.1007/s00280-008-0900-x